


May 21, 2026
August 20, 2026
November 19, 2026

Agenda

- 
1. Roll Call/Call to Order 9:00 AM
2. Ethics Disclosures 9:02 AM
3. Consent Agenda Items 9:03 AM
- A. Review/Approve Meeting Agenda
 - B. Review Lost or Stolen Controlled Substances/DEA 106s - CONFIDENTIAL
 - C. Adverse Drug Events
4. Investigations Review 9:05 AM
- A. Billy Homestead, Senior Investigator
 - i. Review Updated Inspection Form
 - B. Holly Handley, Investigator
 - i. Investigative Report
 - ii. Case # 2023-000147 - EXECUTIVE SESSION
 - iii. Case # 2025-000273 - EXECUTIVE SESSION
 - iv. Case # 2025-000390 - EXECUTIVE SESSION
 - v. Case # 2025-000628 - EXECUTIVE SESSION
 - vi. Case # 2025-000629 - EXECUTIVE SESSION
 - vii. Case # 2025-000630 - EXECUTIVE SESSION
 - viii. Case # 2025-000631 - EXECUTIVE SESSION
 - C. Review & Re-approve (or update) Disciplinary Matrices - EXECUTIVE SESSION
5. Prescription Drug Monitoring Program (PDMP) Update 9:45 AM
- A. Lisa Sherrell, PDMP Manager
6. Division Administrative Operations 10:15 AM
- A. Melissa Dumas, Division Administrative Operations Manager
 - i. Fee Change Project
 - ii. FY26 2nd Quarter Report
 - B. Michael Bowles, Executive Administrator of the Board of Pharmacy
7. Public Comment Period 10:45 AM
- A. Public comments will be kept to 2 minutes per person.
8. Industry Updates 11:00 AM

ALASKA DEPARTMENT OF COMMERCE, COMMUNITY, AND ECONOMIC DEVELOPMENT

A. Tom Wadsworth, PharmD, BCPS - Dean, L.S. Skaggs College of Pharmacy Idaho State University

B. Brandy Seignemartin, PharmD - Executive Director, Alaska Pharmacy Association (AKPhA)

9. Unfinished Board Business 11:30 AM

A. Statutes

i. Current Legislative Matters

a. SB 147 - PHARMACIST PRESCRIPTION AUTHORITY

b. HB 195 - PHARMACIST PRESCRIPTION AUTHORITY

B. Regulations

i. Administrative Order 360 Regulations Reform Plan Approval

10. Adjourn for Lunch 12:30 PM

11. Roll Call/Call to Order 1:00 PM

12. New Board Business 1:05 PM

A. Controlled Substances Advisory Committee Update

i. Sara Rasmussen

B. Rural Health Transformation Program Update

i. Julie McDonald

C. Legislation

i. HB 270 - OPIOID OVERDOSE DRUG PRESCRIPTION

D. Review and Re-up or Change Appointments (Chair, Vice-chair, Secretary)

E. Review and Re-up or Change Delegations of Authority to Executive Administrator to Review Investigative Cases

F. Review and Re-up or Change the Committees Currently in Effect

G. Review and Re-up or Change who the Board Elects as Spokesperson(s) for Legislative Matters

H. Review and Re-up or Change who the Board Elects as Representative for National Organizations or Committees

13. Tasks List Review and Update 4:10 PM

14. Chair Final Comments 4:20 PM

A. Next Quarterly Meeting – May 21, 2026

15. Adjourn

Alaska Board of Pharmacy

Agenda Item #1



Roll Call/Call to Order

Alaska Board of Pharmacy Roster

Board Member Name	Initial Appointment	Reappointed	Term End
Ashley Schaber, PharmD	07/01/2021	03/01/2024	03/01/2028
Sylvain Nouvion, PharmD., Ph.D.	05/31/2023		03/01/2027
Julie McDonald	04/15/2025		03/01/2028
Ramsey Bell, RPh	03/01/2022		03/01/2026
Rebekah Balmes	01/02/2026		03/01/2028
Sara Rasmussen, Public Member	03/01/2023		03/01/2027
Dylan Sanders, Pharmacy Technician	10/28/2024		03/01/2028

Name	Position	Committee Membership/Additional Duties
Ashley Schaber	Chair	Statutes and Regulations
Julie McDonald		
Ramsey Bell		Well-Being
		Compounding, Well-Being
Sara Rasmussen		Statutes and Regulations, Controlled Substances Advisory Committee Chair
Sylvain Nouvion	Secretary	Statutes and Regulations
Dylan Sanders		

Alaska Board of Pharmacy

Agenda Item #2



Ethics Disclosures

Alaska Board of Pharmacy

Agenda Item #3



Consent Agenda Items

Alaska Board of Pharmacy

Agenda Items #4



Investigations Review



THE STATE
of

ALASKA *Department of Commerce, Community, and Economic Development
Division of Corporations, Business and Professional Licensing*

Board of Pharmacy

PO Box 110806, Juneau, AK 99811

Phone: (907) 269-8160

Email: BoardOfPharmacy@Alaska.Gov

Website: ProfessionalLicense.Alaska.Gov/BoardOfPharmacy

Pharmacy Inspection Report Checklist

Inspector Information

Name:				Title:	
Date of Inspection:		Day of the Week:		Time (am/pm):	
Name and Address for Follow-up Report:					
Date Results Shared with Licensee:		Copy Provided to Licensee?	<input type="checkbox"/> Y <input type="checkbox"/> N	Discrepancies?	<input type="checkbox"/> Y <input type="checkbox"/> N

Licensee Information

Pharmacy or Facility Name:					
Representative During Inspection:					
AK License Number:		Phone Number:			
Physical Address:	Street	City	State	Zip	
Pharmacist-in-Charge (PIC):		License Number:			
Date License Issued:		PIC Start Date:			
Was the board notified of PIC appointment? (12 AAC 52.200)		<input type="checkbox"/> Yes <input type="checkbox"/> No			

Inspection Areas

Is the Pharmacist-in-Charge responsible for (12 AAC 52.200-.205):

1. Training of pharmacy personnel? <i>If yes, describe below.</i>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A
2. Do you have a continuous quality improvement (CQI) program in place? <i>If yes, locate, review and describe below.</i>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A

Inspection Areas *(continued)*

3. Maintaining required records? <i>If yes, describe below.</i>	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
4. Reporting theft or loss? <i>If yes, describe procedure below.</i>	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
5. Ensuring effective controls against theft or diversion of prescription drugs? <i>If yes, describe procedure below.</i>	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A

Is a Pharmacy Technician performing any of the following duties?
(Investigator should question staff to make a determination.)

6. Are you receiving verbal prescriptions from a provider?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
7. Are you altering prescriptions without involving a pharmacist?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
8. Do you ever fill a prescription without pharmacist approval?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
9. Do you ever provide patient consultation without a pharmacist's approval?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A

Controlled Substances Act

10. Is the pharmacy secured?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
11. Does the pharmacy have an alarm system?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
12. Does the pharmacy maintain records for all prescriptions for at least two years?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
13. Does the pharmacy quarantine expired drugs? (12 AAC 52.410) <i>If yes, describe procedure below.</i>	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A

Facility Standards (12 AAC 52.400 "Facility Standards for Pharmacies," dated November 2016)

14. Each pharmacy is of sufficient size to allow for the safe and proper storage of prescription drugs and for the safe and proper compounding and/or preparation of prescription drug orders.	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
15. There is a minimum of three linear feet by a minimum of 18 inches in depth of counter working space for each pharmacist or intern compounding or filling prescriptions at the same time.	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
16. The prescription department and all areas where drugs are stored are well lighted, well ventilated, dry, and maintained in a clean and orderly condition. Walls, floors, ceilings, and windows are clean and in general good repair and order.	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A

Inspection Areas (continued)

17. Each pharmacy has a sink with hot and cold running water within the pharmacy and maintained in a sanitary condition.	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
18. There are refrigeration facilities with a thermometer in the prescription department for the proper storage of drugs requiring refrigeration. Temperatures in the refrigerator are maintained within United States Pharmacopoeia standards.	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
19. The temperature of the pharmacy is maintained within a range compatible with the proper storage of drugs. - Room temperature should be 68-77 degrees Fahrenheit. - Cool storage should be 46-59 degrees Fahrenheit.	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
20. Does all staff have access to a current copy of the Alaska Pharmacy Statutes and Regulations?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
21. Does the pharmacy have the phone number of the Poison Control Center?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
22. Display of licensure required. (12 AAC 52.990)	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A

Equipment and Supplies (12 AAC 52.400 "Facility Standards for Pharmacies," dated November 2016)

23. All pharmacies have in their possession the equipment and supplies necessary to compound, dispense, label, administer and distribute drugs and devices. The equipment is in good repair and is available in the practice of pharmacy conducted therein.	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
24. All equipment is kept in a clean and orderly manner. Equipment used in the compounding or preparation of prescription drug orders (counting, weighing, measuring, mixing, stirring, and molding equipment) is clean and in good repair.	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A

PDMP (12 AAC 52.865)

Investigator will provide list of controlled substance prescriptions for random audit generated by PDMP to PIC and request associated pharmacies records submitted to Investigator at the time of inspection or within 10 calendar days of request.			
25. Investigator conducts audit of identified original control substances prescriptions against PDMP data, were they properly reported to the PDMP?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
Investigator will provide Outstanding Controlled Substance Errors list generated by PDMP to the PIC at the time of inspection. The PIC will report any corrections regarding any outstanding errors to the PDMP within 72 hours. (12 AAC 52.865(f)).			
26. Were corrections submitted to the PDMP within 72 hours and/or time frame specified by the investigator?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A

Staff Information

[illegible]

Signature

Investigator Name:			
Investigator Signature:		Date Signed:	

Questions or Additional Information

--



THE STATE
of **ALASKA**

**Department of Commerce, Community,
and Economic Development**

**DIVISION OF CORPORATIONS, BUSINESS AND
PROFESSIONAL LICENSING**

550 West Seventh Avenue, Suite 1500
Anchorage, AK 99501-3567
Main: 907.269.8160
Fax: 907.269.8156

MEMORANDUM

DATE: January 27, 2026
TO: Board of Pharmacy
THRU: Erika Prieksat, Chief Investigator *EP*
FROM: Holly Handley, Investigator
RE: Investigative Report for the February 12, 2026 Meeting

The following information was compiled as an investigative report to the Board for the period of November 04, 2025 thru January 27, 2026; this report includes cases, complaints, and intake matters handled since the last report.

Matters opened by the Paralegals in Anchorage and Juneau, regarding continuing education audits and license action resulting from those matters are covered in this report.

OPEN - 40

<u>Case Number</u>	<u>Violation Type</u>	<u>Case Status</u>	<u>Status Date</u>
OUT OF STATE PHARMACY			
2023-000147	Violation of licensing regulation	Investigation	01/19/2024
PHARMACIST			
2025-000817	Violation of Profession Statute or Regulation	Intake	08/28/2025
2025-001059	License Application Review/Referral	Intake	11/06/2025
2025-000006	Continuing education	Complaint	01/08/2025
2025-000102	Unprofessional conduct	Complaint	07/22/2025
2025-000501	Violation of License Regulation	Complaint	11/20/2025
2025-001023	License Application Review/Referral	Complaint	12/11/2025
2025-001052	License Action in Another State	Complaint	12/31/2025

Alaska Board of Pharmacy

Agenda Item #5



PDMP Update

ALASKA PDMP


PRESCRIPTION DRUG MONITORING PROGRAM Q4 2025

79,559 PATIENTS

Alaskan patients receiving at least one controlled substance prescription.


10,493 REGISTERED USERS

% registered by license type, excluding IHS, military, VA, and delegates.



291,468 SEARCHES

% of searches by user type, excluding IHS, military, VA, and delegates.



85% EHR ACCESS


% of providers using electronic health record system (EHR) integration to search patient information within their clinical workflow.

263 DISPENSERS

Pharmacies or dispensing providers with at least one controlled substance dispensation to Alaska patients.


Data is presented for informational purposes only. Data represents prescription and dispensation activity reported to Alaska Prescription Drug Monitoring Program (PDMP) from October 1, 2025 to December 31, 2025. For more information, visit pdmp.alaska.gov.

195,000 CONTROLLED SUBSTANCE DISPENSATIONS




23 PARTNER STATES

Interstate data sharing including military health system.



Created with mapchart.net

PRESCRIPTION COUNT BY PATIENT AGE & GENDER



Department of Commerce, Community, and Economic Development
Division of Corporations, Business and Professional Licensing

Alaska Board of Pharmacy

Agenda Item #6



Division Administrative Update

Department of Commerce Community, and Economic Development
Corporations, Business and Professional Licensing

Summary of All Professional Licensing
Schedule of Revenues and Expenditures

Board of Pharmacy	FY 20		FY 21	Biennium	FY 22		FY 23	Biennium	FY 24		FY 25	Biennium		FY 26							
														1st & 2nd QTR							
<u>Revenue</u>																					
Revenue from License Fees	\$	631,105	\$	1,121,447	\$	1,752,552	\$	444,975	\$	1,169,195	\$	1,614,170	\$	1,256,105	\$	363,853	\$	1,619,958	\$	147,633	
General Fund Received				\$	-	-		\$	29,810	\$	7,668	37,478		\$	120,240	\$	-	120,240		\$	-
Allowable Third Party Reimbursements	\$	-	\$	-	-		\$	1,650	\$	1,500	3,150		\$	1,588	\$	2,506	4,094		\$	-	
TOTAL REVENUE	\$	631,105	\$	1,121,447	\$	1,752,552	\$	476,435	\$	1,178,363	\$	1,654,798	\$	1,377,933	\$	366,359	\$	1,744,292	\$	147,633	
<u>Expenditures</u>																					
Non Investigation Expenditures																					
1000 - Personal Services		199,334		278,612		477,946		284,719		335,119		619,838		411,918		538,265		950,183		254,579	
2000 - Travel		2,641		-		2,641		6,363		14,252		20,615		11,602		12,223		23,825		-	
3000 - Services		45,283		46,180		91,463		29,584		20,174		49,758		27,965		10,344		38,308		2,283	
4000 - Commodities		521		-		521		82		90		172		300		-		300		-	
5000 - Capital Outlay		-		-		-		-		-		-		-		-		-		-	
Total Non-Investigation Expenditures		247,779		324,792		572,571		320,748		369,635		690,383		451,784		560,831		1,012,616		256,862	
Investigation Expenditures																					
1000-Personal Services		57,738		106,494		164,232		94,519		128,331		222,850		188,437		266,821		455,258		118,733	
2000 - Travel		1,260		-		1,260		5,221		3,182		8,403		-		-		-		2,322	
3023 - Expert Witness		-		-		-		-		-		-		-		-		-		-	
3088 - Inter-Agency Legal		2,537		1,269		3,806		12,011		10,018		22,029		1,739		1,522		3,261		2,271	
3094 - Inter-Agency Hearing/Mediation		694		152		846		1,758		68		1,826		15,943		-		15,943		-	
3000 - Services other		269		216		485		338		545		883		675		322		997		39	
4000 - Commodities		-		-		-		-		10		10		-		-		-		-	
Total Investigation Expenditures		62,498		108,131		170,629		113,847		142,155		256,001		206,794		268,665		475,459		123,365	
Total Direct Expenditures		310,277		432,923		743,200		434,595		511,790		946,384		658,578		829,496		1,488,075		380,227	
Indirect Expenditures																					
Internal Administrative Costs		164,443		191,897		356,340		182,236		190,056		372,292		204,294		223,291		427,585		111,646	
Departmental Costs		58,131		75,431		133,562		76,951		76,872		153,823		102,391		131,642		234,033		65,821	
Statewide Costs		33,868		52,856		86,724		47,667		50,400		98,067		58,103		68,693		126,796		34,347	
Total Indirect Expenditures		256,442		320,184		576,626		306,854		317,328		624,182		364,788		423,626		788,414		211,814	
						-															
TOTAL EXPENDITURES	\$	566,719	\$	753,107	\$	1,319,826	\$	741,449	\$	829,118	\$	1,570,566	\$	1,023,366	\$	1,253,122	\$	2,276,489	\$	592,041	
<u>Cumulative Surplus (Deficit)</u>																					
Beginning Cumulative Surplus (Deficit)	\$	154,844	\$	219,230			\$	587,570	\$	322,556			\$	671,801	\$	1,026,368			\$	139,604	
Annual Increase/(Decrease)		64,386		368,340				(265,014)		349,245				354,567		(886,764)				(444,408)	
Ending Cumulative Surplus (Deficit)	\$	219,230	\$	587,570			\$	322,556	\$	671,801			\$	1,026,368	\$	139,604			\$	(304,804)	
<u>Statistical Information</u>																					
Number of Licenses for Indirect calculation		5,934		6,917				6,542		6,428				6,856		6,887					
<u>Additional information:</u>																					
• General fund dollars were received in FY21-FY24 to offset increases in personal services and help prevent programs from going int																					
• Most recent fee change: Fee repealed FY25																					
• Annual license fee analysis will include consideration of other factors such as board and licensee input, potential investigation load, court cases, multiple license and fee types under one progri																					

Appropriation Name (Ex)	(Multiple Items)
Sub Unit	(All)
PL Task Code	PHA1

Sum of Budgetary Expenditures	Object Type Name (Ex)			
Object Name (Ex)	1000 - Personal Services	2000 - Travel	3000 - Services	Grand Total
1011 - Regular Compensation	196,662.08			196,662.08
1021 - Allowances to Employees	180.00			180.00
1023 - Leave Taken	29,649.98			29,649.98
1028 - Alaska Supplemental Benefit	13,905.01			13,905.01
1030 - Public Employee's Retirement System Defined Contribution	11,284.37			11,284.37
1034 - Public Employee's Retirement System Defined Cont Health Reim	6,909.97			6,909.97
1035 - Public Employee's Retirement Sys Defined Cont Retiree Medical	1,852.13			1,852.13
1037 - Public Employee's Retirement Sys Defined Benefit Unfnd Liab	40,956.94			40,956.94
1039 - Unemployment Insurance	1,054.44			1,054.44
1040 - Group Health Insurance	57,499.18			57,499.18
1041 - Basic Life and Travel	73.14			73.14
1042 - Worker's Compensation Insurance	2,401.71			2,401.71
1047 - Leave Cash In Employer Charge	5,019.43			5,019.43
1048 - Terminal Leave Employer Charge	2,172.55			2,172.55
1053 - Medicare Tax	3,107.70			3,107.70
1062 - GGU Business Leave Bank Contributions	316.92			316.92
1077 - ASEA Legal Trust	148.33			148.33
1079 - ASEA Injury Leave Usage	27.95			27.95
1080 - SU Legal Trst	90.09			90.09
2000 - In-State Employee Taxable Airfare			878.29	878.29
2001 - In-State Employee Taxable Surface Transportation			332.13	332.13
2002 - In-State Employee Taxable Lodging			782.00	782.00
2003 - In-State Employee Non-Taxable Meals and Incidentals			330.00	330.00
3035 - Long Distance			26.13	26.13
3045 - Postage			39.60	39.60
3050 - Disposal			1,470.24	1,470.24
3088 - Inter-Agency Legal			3,057.08	3,057.08
Grand Total	373,311.92	2,322.42	4,593.05	380,227.39

Alaska Board of Pharmacy

Agenda Item #7



Public Comment Period

Alaska Board of Pharmacy

Agenda Item #8



Industry Updates



UAA/ISU Doctor of
Pharmacy Program
UNIVERSITY of ALASKA ANCHORAGE


Update for the Alaska Board of Pharmacy

Presented by
Dr. Tom Wadsworth
Dean | Associate Professor

Transparency on University Reorganization

Broader Context

Idaho State University may undergo institutional reorganization in response to state budget pressures affecting higher education across Idaho.

 **Critical Assurance:** These potential changes will not impact the UAA-ISU Doctor of Pharmacy campus, operations, faculty, students, or accreditation status.

We're sharing this proactively to maintain transparency with our Alaska partners. The pharmacy program remains fully protected and prioritized.

Campus Operations

Fully maintained and independently supported

Faculty & Staff

No changes to positions or responsibilities


Student Experience

Unaffected curriculum and support services

Accreditation

Full compliance maintained without interruption

Strong Enrollment Momentum



Ahead of Schedule

The Alaska campus currently has **10 seats filled**, exceeding enrollment at this point in previous cycles and demonstrating continued program strength.

Quality Growth

We're experiencing robust growth in both applicant volume and quality. Incoming students show strong academic credentials, professional maturity, and genuine commitment to serving Alaska communities.

Application metrics indicate sustained interest in pharmacy careers and confidence in our program's value proposition.

Transforming Campus Culture

Over the past three years, we've undertaken a comprehensive institutional culture change effort focused on creating an environment where everyone thrives.



Enhanced Faculty Experience

Improved working conditions, professional development opportunities, and collaborative decision-making processes



Elevated Staff Experience

Recognition of contributions, streamlined processes, and meaningful engagement in program success



Enriched Student Experience

Responsive support systems, clear communication channels, and commitment to student success and well-being

Rededication to Excellence



Our culture transformation reflects a rededication to the core values that define excellent pharmacy education and professional preparation.



Professionalism

Modeling the behaviors and standards we expect in practice



Trust & Respect

Building authentic relationships across all program levels



Clear Communication

Transparent, timely, and constructive dialogue




Shared Purpose

United commitment to student success and patient care

Partnership with Alaska Pharmacists Association

The College of Pharmacy enthusiastically supports the Alaska Pharmacists Association and its critical legislative and professional initiatives advancing pharmacy practice throughout the state.




Investing in Student Advocacy

Building Tomorrow's Leaders

Our matching funds program demonstrates tangible commitment to developing pharmacists who understand policy, engage with legislators, and advocate effectively for patients and the profession.

By supporting student participation in legislative sessions, we're cultivating the next generation of pharmacy leaders who will shape healthcare policy in Alaska.



This collaborative model ensures students gain real-world experience in professional advocacy while strengthening pharmacy's voice in the state capital.

Moving Forward Together



The UAA-ISU Doctor of Pharmacy Program stands on solid ground. We're grateful for our partnership with the Alaska Board of Pharmacy, AKPhA, and Alaska's entire pharmacy community.

Together, we're building a sustainable pipeline of exceptional pharmacists committed to serving Alaska's patients, expanding access to care, and strengthening workforce capacity across the state.

Thank you for your continued collaboration and trust.

PARTNERSHIP

PROGRESS

COMMITMENT

Alaska Pharmacy Association: Industry Update

Brandy Seignemartin, PharmD,
Executive Director
Brittany Keener, PharmD, MPH,
BCPS, FAKPhA
President



National Recognition and the Unified Pharmacy Ecosystem



Recognition and Ecosystem

Building a unified pharmacy framework

ASHP PHARMACY CHAMPION AWARD

The ASHP Pharmacy Champion Award recognizes exemplary leadership and **dedication** in advancing pharmacy practice within Alaska, showcasing the impact of collaborative efforts among professionals in the field.

ALASKA PHARMACY TRIAD

The Alaska Pharmacy Triad represents a **collaborative** initiative involving the Board of Pharmacy, UAA-ISU, and AKPhA, aimed at fostering a robust pharmacy practice environment through unified policies and support.

The 2026 Turning Point in Rural Health



Opportunities Ahead

Rural Health Transformation Program



SUPPORT FOR PAYMENT FOR SERVICES

The state committed significant resources toward building sustainable pharmacy service models

SPARKING TECHNOLOGY

What technology resources are needed to improve workflow efficiency and provide more, higher quality care

PROPOSALS

We are working with multiple stakeholders on building a proposal to support pharmacies critical role in transforming our healthcare delivery system & improving the health of Alaskans.

The Alaska Pharmacy Triad: Legislative & Regulatory Update



Alaska Pharmacy Triad

Key Roles and Legislative Highlights

SB147 / HB 195

- The bills remain active in interim and committee discussions
- Stakeholder engagement is ongoing across the healthcare system
- Alignment with the Rural Health Transformation Program continues to strengthen the policy case

HB 226 REGULATIONS PACKAGE

Public Hearing is March 5 at 11:00 am.

Regs Notice

Upcoming Events

- AKPhA Legislative Fly-in Feb 3-5, Hosting joint reception with Alaska Native Health Board
- 60th Annual Convention & Tradeshow Feb 20-22 @ Hotel Captain Cook
- Friday night joint advocacy fund fundraiser: Casino Night!





EMAIL

brandy@alaskapharmacy.org

SOCIAL MEDIA

Follow us on Facebook & LinkedIn



Alaska Board of Pharmacy

Agenda Item #9



Unfinished Board Business

CS FOR SENATE BILL NO. 147(L&C)

IN THE LEGISLATURE OF THE STATE OF ALASKA

THIRTY-FOURTH LEGISLATURE - FIRST SESSION

BY THE SENATE LABOR AND COMMERCE COMMITTEE

Offered: 5/12/25

Referred:

Sponsor(s): SENATOR GIESSEL BY REQUEST

A BILL

FOR AN ACT ENTITLED

1 **"An Act relating to the prescription and administration of drugs and devices by**
2 **pharmacists; relating to reciprocity for pharmacists; and providing for an effective**
3 **date."**

4 **BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF ALASKA:**

5 * **Section 1.** AS 08.80.030(b) is amended to read:

6 (b) In order to fulfill its responsibilities, the board has the powers necessary
7 for implementation and enforcement of this chapter, including the power to

8 (1) elect a president and secretary from its membership and adopt rules
9 for the conduct of its business;

10 (2) license by examination or by license transfer the applicants who are
11 qualified to engage in the practice of pharmacy;

12 (3) assist the department in inspections and investigations for
13 violations of this chapter, or of any other state or federal statute relating to the practice
14 of pharmacy;

- 1 (4) adopt regulations to carry out the purposes of this chapter;
- 2 (5) establish and enforce compliance with professional standards and
- 3 rules of conduct for pharmacists engaged in the practice of pharmacy;
- 4 (6) determine standards for recognition and approval of degree
- 5 programs of schools and colleges of pharmacy whose graduates shall be eligible for
- 6 licensure in this state, including the specification and enforcement of requirements for
- 7 practical training, including internships;
- 8 (7) establish for pharmacists and pharmacies minimum specifications
- 9 for the physical facilities, technical equipment, personnel, and procedures for the
- 10 storage, compounding, and dispensing of drugs or related devices, and for the
- 11 monitoring of drug therapy, including independent monitoring of drug therapy;
- 12 (8) enforce the provisions of this chapter relating to the conduct or
- 13 competence of pharmacists practicing in the state, and the suspension, revocation, or
- 14 restriction of licenses to engage in the practice of pharmacy;
- 15 (9) license and regulate the training, qualifications, and employment of
- 16 pharmacy interns and pharmacy technicians;
- 17 (10) license and regulate the qualifications of entities and individuals
- 18 engaged in the manufacture or distribution of drugs and related devices;
- 19 (11) establish and maintain a controlled substance prescription
- 20 database as provided in AS 17.30.200;
- 21 (12) establish standards for the independent prescribing and
- 22 administration of vaccines and related emergency medications under AS 08.80.168,
- 23 including the completion of an immunization training program approved by the board
- 24 and an epinephrine auto-injector training program under AS 17.22.020(b);
- 25 (13) establish standards for the independent prescribing and dispensing
- 26 by a pharmacist of an opioid overdose drug under AS 17.20.085, including the
- 27 completion of an opioid overdose training program approved by the board;
- 28 (14) require that a licensed pharmacist who **prescribes, administers,**
- 29 **or** dispenses a **schedule IA, IIA, IIIA, IVA, or VA controlled substance under**
- 30 **state law or** schedule II, III, [OR] IV, **or V** controlled substance under federal law to a
- 31 person in the state register with the controlled substance prescription database under

1 AS 17.30.200(n);

2 (15) establish the qualifications and duties of the executive
3 administrator and delegate authority to the executive administrator that is necessary to
4 conduct board business;

5 (16) license and inspect the facilities of pharmacies, manufacturers,
6 wholesale drug distributors, third-party logistics providers, and outsourcing facilities
7 located outside the state under AS 08.80.159;

8 (17) license Internet-based pharmacies providing services to residents
9 in the state;

10 (18) adopt regulations pertaining to retired pharmacist status.

11 * **Sec. 2.** AS 08.80.110 is amended to read:

12 **Sec. 08.80.110. Qualifications for licensure by examination.** An applicant
13 for licensure as a pharmacist shall

14 (1) be fluent in the reading, writing, and speaking of the English
15 language;

16 (2) be a graduate of a college in a degree program approved by the
17 board;

18 (3) pass an examination or examinations given by the board or
19 acceptable to the board under the score transfer process administered by the National
20 Association of Boards of Pharmacy;

21 (4) have completed internship training or another program that has
22 been approved by the board or demonstrated to the board's satisfaction that the
23 applicant has experience in the practice of pharmacy that meets or exceeds the
24 minimum internship requirements of the board; and

25 5 receive education in pain management and opioid use and
26 addiction, unless the applicant has demonstrated to the satisfaction of the board
27 that the applicant does not currently hold a valid federal Drug Enforcement
28 Administration registration number; an applicant may include past professional
29 experience or professional education as proof of professional competence.

30 * **Sec. 3.** AS 08.80.145 is amended to read:

31 **Sec. 08.80.145. Reciprocity; license transfer.** If another jurisdiction allows

1 licensure in that jurisdiction of a pharmacist licensed in this state under conditions
 2 similar to those in this section, the board may license as a pharmacist in this state a
 3 person licensed as a pharmacist in the other jurisdiction if the person

4 (1) submits a written application to the board on a form required by the
 5 board;

6 (2) is at least 18 years of age;

7 (3) possesses at the time of the request for licensure as a pharmacist in
 8 this state the qualifications necessary to be eligible for licensure in this state;

9 (4) has engaged in the practice of pharmacy for at least one year
 10 immediately before applying for a license under this section;

11 (5) presents proof satisfactory to the board that the person is currently
 12 licensed as a pharmacist in the other jurisdiction and does not currently have a
 13 pharmacist license suspended, revoked, or otherwise restricted except for failure to
 14 apply for renewal or failure to obtain the required continuing education credits;

15 (6) has passed an examination approved by the board that tests the
 16 person's knowledge of Alaska laws relating to pharmacies and pharmacists and the
 17 regulations adopted under those laws; [AND]

18 (7) meets the requirements of AS 08.80.110(5); and

19 (8) pays all required fees.

20 * **Sec. 4.** AS 08.80.165 is amended to read:

21 **Sec. 08.80.165. Continuing education requirements.** The board shall
 22 establish requirements for continuing education in pharmacy that must be satisfied
 23 before a license issued under this chapter may be renewed. The continuing education
 24 requirements must include at least two hours of education in pain management
 25 and opioid use and addiction in the two years preceding an application for
 26 renewal of a license. The board may exempt a licensee from the requirement to
 27 receive at least two hours of education in pain management and opioid use and
 28 addiction if the licensee demonstrates to the satisfaction of the board that

29 1 the licensee's practice does not include pain management and
 30 opioid prescription or administration; or

31 (2) the licensee does not currently hold a valid federal Drug

Enforcement Administration registration number.

* **Sec. 5.** AS 08.80.337(a) is amended to read:

a A pharmacist may, under a collaborative practice agreement with a written protocol approved by a practitioner **who is not a pharmacist**, provide patient care services.

* **Sec. 6.** AS 08.80.337(d) is amended to read:

(d) In this section, "patient care services" means medical care services, **including the prescription or administration of a drug or device to a patient, that are** given in exchange for compensation **and** intended to achieve outcomes related to the cure or prevention of a disease, elimination or reduction of a patient's symptoms, or arresting or slowing of a disease process; **"patient care services" does not include the prescription of an abortion-inducing drug to a patient.**

* **Sec. 7.** AS 08.80.337 is amended by adding a new subsection to read:

(e) A pharmacist prescribing or administering a drug or device under this section shall recognize the limits of the pharmacist's education, training, and experience and consult with and refer to other practitioners as appropriate.

* **Sec. 8.** AS 08.80.480(30) is amended to read:

(30) "practice of pharmacy" means the interpretation, evaluation, and dispensing of prescription drug orders in the patient's best interest; participation in drug and device selection, drug administration, drug regimen reviews, and drug or drug-related research; provision of patient counseling and the provision of those acts or services necessary to provide pharmaceutical care; the independent prescribing, dispensing, and administration of drugs in accordance with AS 08.80.168; **providing patient care services in accordance with AS 08.80.337;** the responsibility for compounding and labeling of drugs and devices except labeling by a manufacturer, repackager, or distributor of nonprescription drugs and commercially packaged legend drugs and devices; proper and safe storage of drugs and devices; and maintenance of proper records for them;

* **Sec. 9.** AS 08.80.480 is amended by adding a new paragraph to read:

(40) "opioid" includes the opium and opiate substances and opium and opiate derivatives listed in AS 11.71.140 and 11.71.160.

- 1 * **Sec. 10.** AS 08.80.337(c) is repealed.
- 2 * **Sec. 11.** This Act takes effect January 1, 2026.

HOUSE BILL NO. 195

IN THE LEGISLATURE OF THE STATE OF ALASKA

THIRTY-FOURTH LEGISLATURE - FIRST SESSION

BY REPRESENTATIVES MINA, Gray, Prax

Introduced: 4/15/25

Referred: Health and Social Services, Labor and Commerce, Finance

A BILL

FOR AN ACT ENTITLED

1 **"An Act relating to the prescription and administration of drugs and devices by**
2 **pharmacists; relating to reciprocity for pharmacists; and providing for an effective**
3 **date."**

4 **BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF ALASKA:**

5 *** Section 1.** AS 08.80.030(b) is amended to read:

6 (b) In order to fulfill its responsibilities, the board has the powers necessary
7 for implementation and enforcement of this chapter, including the power to

8 (1) elect a president and secretary from its membership and adopt rules
9 for the conduct of its business;

10 (2) license by examination or by license transfer the applicants who are
11 qualified to engage in the practice of pharmacy;

12 (3) assist the department in inspections and investigations for
13 violations of this chapter, or of any other state or federal statute relating to the practice
14 of pharmacy;

- 1 (4) adopt regulations to carry out the purposes of this chapter;
- 2 (5) establish and enforce compliance with professional standards and
- 3 rules of conduct for pharmacists engaged in the practice of pharmacy;
- 4 (6) determine standards for recognition and approval of degree
- 5 programs of schools and colleges of pharmacy whose graduates shall be eligible for
- 6 licensure in this state, including the specification and enforcement of requirements for
- 7 practical training, including internships;
- 8 (7) establish for pharmacists and pharmacies minimum specifications
- 9 for the physical facilities, technical equipment, personnel, and procedures for the
- 10 storage, compounding, and dispensing of drugs or related devices, and for the
- 11 monitoring of drug therapy, including independent monitoring of drug therapy;
- 12 (8) enforce the provisions of this chapter relating to the conduct or
- 13 competence of pharmacists practicing in the state, and the suspension, revocation, or
- 14 restriction of licenses to engage in the practice of pharmacy;
- 15 (9) license and regulate the training, qualifications, and employment of
- 16 pharmacy interns and pharmacy technicians;
- 17 (10) license and regulate the qualifications of entities and individuals
- 18 engaged in the manufacture or distribution of drugs and related devices;
- 19 (11) establish and maintain a controlled substance prescription
- 20 database as provided in AS 17.30.200;
- 21 (12) establish standards for the independent prescribing and
- 22 administration of vaccines and related emergency medications under AS 08.80.168,
- 23 including the completion of an immunization training program approved by the board
- 24 and an epinephrine auto-injector training program under AS 17.22.020(b);
- 25 (13) establish standards for the independent prescribing and dispensing
- 26 by a pharmacist of an opioid overdose drug under AS 17.20.085, including the
- 27 completion of an opioid overdose training program approved by the board;
- 28 (14) require that a licensed pharmacist who **prescribes, administers,**
- 29 **or** dispenses a **schedule IA, IIA, IIIA, IVA, or VA controlled substance under**
- 30 **state law or** schedule II, III, [OR] IV, **or V** controlled substance under federal law to a
- 31 person in the state register with the controlled substance prescription database under

AS 17.30.200(n);

(15) establish the qualifications and duties of the executive administrator and delegate authority to the executive administrator that is necessary to conduct board business;

(16) license and inspect the facilities of pharmacies, manufacturers, wholesale drug distributors, third-party logistics providers, and outsourcing facilities located outside the state under AS 08.80.159;

(17) license Internet-based pharmacies providing services to residents in the state;

(18) adopt regulations pertaining to retired pharmacist status.

* **Sec. 2.** AS 08.80.110 is amended to read:

Sec. 08.80.110. Qualifications for licensure by examination. An applicant for licensure as a pharmacist shall

(1) be fluent in the reading, writing, and speaking of the English language;

(2) be a graduate of a college in a degree program approved by the board;

(3) pass an examination or examinations given by the board or acceptable to the board under the score transfer process administered by the National Association of Boards of Pharmacy;

(4) have completed internship training or another program that has been approved by the board or demonstrated to the board's satisfaction that the applicant has experience in the practice of pharmacy that meets or exceeds the minimum internship requirements of the board; and

5 receive education in pain management and opioid use and addiction, unless the applicant has demonstrated to the satisfaction of the board that the applicant does not currently hold a valid federal Drug Enforcement Administration registration number; an applicant may include past professional experience or professional education as proof of professional competence.

* **Sec. 3.** AS 08.80.145 is amended to read:

Sec. 08.80.145. Reciprocity; license transfer. If another jurisdiction allows

1 licensure in that jurisdiction of a pharmacist licensed in this state under conditions
 2 similar to those in this section, the board may license as a pharmacist in this state a
 3 person licensed as a pharmacist in the other jurisdiction if the person

4 (1) submits a written application to the board on a form required by the
 5 board;

6 (2) is at least 18 years of age;

7 (3) possesses at the time of the request for licensure as a pharmacist in
 8 this state the qualifications necessary to be eligible for licensure in this state;

9 (4) has engaged in the practice of pharmacy for at least one year
 10 immediately before applying for a license under this section;

11 (5) presents proof satisfactory to the board that the person is currently
 12 licensed as a pharmacist in the other jurisdiction and does not currently have a
 13 pharmacist license suspended, revoked, or otherwise restricted except for failure to
 14 apply for renewal or failure to obtain the required continuing education credits;

15 (6) has passed an examination approved by the board that tests the
 16 person's knowledge of Alaska laws relating to pharmacies and pharmacists and the
 17 regulations adopted under those laws; [AND]

18 (7) meets the requirements of AS 08.80.110(5); and

19 (8) pays all required fees.

20 * **Sec. 4.** AS 08.80.165 is amended to read:

21 **Sec. 08.80.165. Continuing education requirements.** The board shall
 22 establish requirements for continuing education in pharmacy that must be satisfied
 23 before a license issued under this chapter may be renewed. The continuing education
 24 requirements must include at least two hours of education in pain management
 25 and opioid use and addiction in the two years preceding an application for
 26 renewal of a license. The board may exempt a licensee from the requirement to
 27 receive at least two hours of education in pain management and opioid use and
 28 addiction if the licensee demonstrates to the satisfaction of the board that

29 1 the licensee's practice does not include pain management and
 30 opioid prescription or administration; or

31 (2) the licensee does not currently hold a valid federal Drug

Enforcement Administration registration number.

* **Sec. 5.** AS 08.80.337(a) is amended to read:

a A pharmacist may, under a collaborative practice agreement with a written protocol approved by a practitioner **who is not a pharmacist**, provide patient care services.

* **Sec. 6.** AS 08.80.337(d) is amended to read:

(d) In this section, "patient care services" means medical care services, **including the prescription or administration of a drug or device to a patient, that are** given in exchange for compensation **and** intended to achieve outcomes related to the cure or prevention of a disease, elimination or reduction of a patient's symptoms, or arresting or slowing of a disease process.

* **Sec. 7.** AS 08.80.337 is amended by adding a new subsection to read:

(e) A pharmacist prescribing or administering a drug or device under this section shall recognize the limits of the pharmacist's education, training, and experience and consult with and refer to other practitioners as appropriate.

* **Sec. 8.** AS 08.80.480(30) is amended to read:

(30) "practice of pharmacy" means the interpretation, evaluation, and dispensing of prescription drug orders in the patient's best interest; participation in drug and device selection, drug administration, drug regimen reviews, and drug or drug-related research; provision of patient counseling and the provision of those acts or services necessary to provide pharmaceutical care; the independent prescribing, dispensing, and administration of drugs in accordance with AS 08.80.168; **providing patient care services in accordance with AS 08.80.337;** the responsibility for compounding and labeling of drugs and devices except labeling by a manufacturer, repackager, or distributor of nonprescription drugs and commercially packaged legend drugs and devices; proper and safe storage of drugs and devices; and maintenance of proper records for them;

* **Sec. 9.** AS 08.80.480 is amended by adding a new paragraph to read:

(40) "opioid" includes the opium and opiate substances and opium and opiate derivatives listed in AS 11.71.140 and 11.71.160.

* **Sec. 10.** AS 08.80.337(c) is repealed.

1 * **Sec. 11.** This Act takes effect January 1, 2026.

Alaska Board of Pharmacy

Agenda Item #10



Adjourn for Lunch

Alaska Board of Pharmacy

Agenda Item #11



Roll Call/Call to Order

Alaska Board of Pharmacy

Agenda Item #12



New Board Business

HOUSE BILL NO. 270

IN THE LEGISLATURE OF THE STATE OF ALASKA

THIRTY-FOURTH LEGISLATURE - SECOND SESSION

BY REPRESENTATIVES TOMASZEWSKI, Underwood

Introduced: 1/23/26

Referred: Health and Social Services, Labor and Commerce

A BILL**FOR AN ACT ENTITLED**

1 "An Act relating to the prescription of opioid overdose drugs."

2 **BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF ALASKA:**

3 * **Section 1.** AS 08.36.355(c) is amended by adding a new paragraph to read:

4 (4) "opioid overdose drug" has the meaning given in AS 17.20.085(g).

5 * **Sec. 2.** AS 08.36.355 is amended by adding a new subsection to read:

6 (d) A licensee who issues a prescription for an opioid to a patient shall offer
7 the patient a prescription for an opioid overdose drug if

8 (1) the prescription is for an opioid that exceeds a three-day supply;

9 (2) the prescription is for a total daily opioid dosage representing a
10 morphine milligram equivalent of 50 milligrams or more;

11 (3) the patient is concurrently prescribed a benzodiazepine; or

12 (4) the patient has a history of overdose or substance use disorder.

13 * **Sec. 3.** AS 08.64.363(c) is amended by adding a new paragraph to read:

14 (4) "opioid overdose drug" has the meaning given in AS 17.20.085(g).

15 * **Sec. 4.** AS 08.64.363 is amended by adding a new subsection to read:

(d) A licensee who issues a prescription for an opioid to a patient shall offer the patient a prescription for an opioid overdose drug if

- (1) the prescription is for an opioid that exceeds a three-day supply;
- (2) the prescription is for a total daily opioid dosage representing a morphine milligram equivalent of 50 milligrams or more;
- (3) the patient is concurrently prescribed a benzodiazepine; or
- (4) the patient has a history of overdose or substance use disorder.

* **Sec. 5.** AS 08.68.705(d) is amended by adding a new paragraph to read:

- (4) "opioid overdose drug" has the meaning given in AS 17.20.085(g).

* **Sec. 6.** AS 08.68.705 is amended by adding a new subsection to read:

(e) An advanced practice registered nurse who issues a prescription for an opioid to a patient shall offer the patient a prescription for an opioid overdose drug if

- (1) the prescription is for an opioid that exceeds a three-day supply;
- (2) the prescription is for a total daily opioid dosage representing a morphine milligram equivalent of 50 milligrams or more;
- (3) the patient is concurrently prescribed a benzodiazepine; or
- (4) the patient has a history of overdose or substance use disorder.

* **Sec. 7.** AS 08.72.276 is amended by adding new subsections to read:

(c) A licensee who issues a prescription for an opioid to a patient shall offer the patient a prescription for an opioid overdose drug if

- (1) the prescription is for an opioid that exceeds a three-day supply;
- (2) the prescription is for a total daily opioid dosage representing a morphine milligram equivalent of 50 milligrams or more;
- (3) the patient is concurrently prescribed a benzodiazepine; or
- (4) the patient has a history of overdose or substance use disorder.

(d) In this section, "opioid overdose drug" has the meaning given in AS 17.20.085(g).

Alaska Board of Pharmacy

Agenda Item #13



Tasks List Review and Update

ALASKA BOARD OF PHARMACY

TASK LIST - ACTION ITEMS

(as of 01/02/2026)

Incomplete Action Items from Previous Meetings	
	Task for the board to track what other state boards are doing with AI. (Dylan Sanders is spearheading)
	Task for Michael Bowles to reach out to the Alaska Department of Health and request a representative provide a presentation to the board on harm reduction and Buprenorphine in EMS in Alaska.
	Task for Ashley Schaber to draft the letter in support of the Ensuring Community Access to Pharmacy Act (ECAPS) HR 3124 and SB 2426 and Michael Bowles to submit the letter to OnBoard for a vote.
	Task for Michael Bowles to add the final report from the Collaboration Addressing Workforce Well-Being to the November meeting agenda.
	Task for Sylvain Nouvion to review the information from the Implementing Solutions Summit 2.0: Building a Sustainable, Healthy, Pharmacy Workforce and Workplace event. Present to the board at the November meeting.
Action Items from the November 20, 2025, Meeting	
	Task for Michael Bowles to add vice chairperson vote to the February agenda.
	Task for Michael Bowles to add the fee change project to February agenda.
	Task for Michael Bowles to send out via listserv the Medicaid info provided to the Board during Dr. Semling's update.
	Task for Michael Bowles to create a survey to find what dates and times work best for workgroup.
	Task for Michael Bowles to find out if statute changes to AS 08.80.157 and 08.80.330 can occur under AO360. No – The legislative process cannot be bypassed.
	Task for the board to review the investigations inspection form at the February meeting.
	Task for Sylvain Nouvion to provide Michael Bowles a summary of the meeting as a newsletter to send as a listserv.

	Not Started
	In Process
	Complete

Alaska Board of Pharmacy

Agenda Item #14



Chair Final Comments

Alaska Board of Pharmacy

Agenda Item #15



Adjourn